future scope of antioxidants in clinical medicine
TRANSCRIPT
![Page 1: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/1.jpg)
FUTURE SCOPE OF ANTIOXIDANTS IN CLINICAL MEDICINE
Dr Indla Yogananda ReddyProfessor of Physiology
![Page 2: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/2.jpg)
Objectives 1. Free Radicals Friends or Foes2. Pro-oxidant effect of antioxidant3. Why to look for the future scope of the
antioxidants in clinical practice4. What are the real future prospects of
antioxidants in clinical practice
![Page 3: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/3.jpg)
Free Radicals Friends or Foes1. Generation of ATP – oxidative
phosphorylation2. Detoxification of xenobiotics-Cytochrome
P4503. Apoptosis of effete or defective cells4. Killing of micro-organisms and cancer cells5. Oxygenases (Cox, Lox)- for the synthesis of
prostaglandins & leukotrines6. ROS-second messengers7. Redox signaling pathway
![Page 4: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/4.jpg)
Pro-oxidant effect of Antioxidant1. Ascorbate-high ferric ion-↑ lipid peroxidation2. Ascorbate-↑ DNA damage3. Vitamin E- pro-oxidant4. Beta-carotene-pro-oxidant-lungs-smokers5. Signal transduction for ROS-inhibited
![Page 5: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/5.jpg)
Meta-anlyses of RCT of N-Acetylcystine in various diseases
Publication No of RCT/randomized patients
Disease Results conclusion
Adabag et al 10/1163 Post cardiac surgery
No change in mortality
No conclusive evidence on the ben Rx
Nigwekar et a 12/1324 post-cardiovascula
No significant change in ARF or mortality
No conclusive evidence on the ben Rx
Mckay et al 6/ Liver transplantati
No improvement in clinical outcome
No conclusive evidence on the ben Rx
Ho et al 10/1193 After major surgeries
No significant decrease in ARF or mortality
No conclusive evidence on the ben Rx
Sutherland et 8/2214 COPD Significant decrease in exacerbation
Treatment is beneficial
![Page 6: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/6.jpg)
Why many antioxidants have failed to show efficacy in interventional human studies 1. Oxidative stress is not the primary cause of the disease2. Oxidative stress is not the only cause of the disease3. Patients do not equally benefit from antioxidant
therapy4. Administered antioxidant is not able to lower oxidative
stress5. Antioxidant molecule has harmful effects that Mask
its useful antioxidant actions6. Certain antioxidants are not effective in well-nourished
population 7. The target is not well selected
![Page 7: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/7.jpg)
Oxidative stress is not the primary cause of the diseaseEarly or late stage of the tissue injury
Oxidative stress is not the only cause of the diseaseEg; 1. lack of success in lung disease 2. ischemic cell death in stroke
Patients do not equally benefit from antioxidant therapyOxidative stress status is different from patient to patientPatient selection should be based on their oxidative stress status↓ efficacy of vitamin EPharmacogenomics should be considered Eg; selection of diabetic patients-haptoglobin-vitamin E
![Page 8: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/8.jpg)
Administered antioxidant is not able to lower oxidative stressDNA oxidative markers in urine ↓- Brussels sprouts but not with β-carotene, vitamin C, α-tocopherolCombination of antioxidants ↑ DNA oxidative damage1. Antioxidant molecule has low bioavailability2. Time and duration of therapy are not optimala. population-oxidative stress for decadesb. optimal duration of therapy3. Oxidative stress is hard to overcome in certain diseaseEg; balance between pro-oxidants and antioxidants
![Page 9: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/9.jpg)
4. Antioxidants have poor target specificityEg; cancer, neurodegenerative diseases5. Reaction products of the antioxidants are toxicPro-oxidants+antioxidants=free radicalsEg; Edaravone 6. Single antioxidant is not enough to overcome oxidative stressEg; Vitamin E with vitamin C7. Physiological mechanisms prevent the achievement of high tissue level of antioxidantsEg; endogenous control mechanisms
![Page 10: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/10.jpg)
Antioxidants have harmful effects that masks their useful antioxidant actionsi. β-carotene can have unwanted effects on lipid profileii. Vitamin E- may prevent the increase in HDL-2Certain antioxidants are not effective in well nourished populationEg; 1. Vitamins may prevent cancer in patients with poor
nutritional status 2. Should not generalise this notion to all antioxidantsEg; B12-dementia-↓ plasma B12-cognition 3. Antioxidants are probably more effective in developing
countries 4. Lutein and green tea in adequately nourished patients-plasma
oxidative stress parameters are not altered
![Page 11: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/11.jpg)
The target is not well selectedRight target for therapyEg; SOD mimetic may not be successful-endogenous SOD functions very effectively
![Page 12: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/12.jpg)
Near future directions of antioxidants should be in overcoming these drawbacks
Oxidative stress is not the primary cause of the disease-selection of diseases in which oxidative stress is the core pathology
Oxidative stress is not the only cause of the disease-combination of antioxidants with other drugs
Patients do not equally benefit from antioxidant therapy-with the use of biomarkers of oxidative stress select the patients with high oxidative stress
![Page 13: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/13.jpg)
Antioxidants have low bioavailability-optimization of antioxidant levels (nano-carriers)
Time and duration of therapy are not optimal-optimization of the time and duration of antioxidant therapy, use of biomarkers to monitor the response to antioxidant therapy
Oxidative stress is hard to overcome in certain diseases-use of combination of antioxidants
Antioxidants have poor target specificity-use of antioxidants on disease specific pathways rather universal pathways (nano-carriers)
Reaction products of the antioxidants are toxic-optimization of antioxidants
![Page 14: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/14.jpg)
A single antioxidant is not enough to overcome oxidative stress-use of combination of antioxidantsPhysiological mechanisms prevent the achievements of high tissue levels of antioxidants-selection of antioxidants that can overcome this effect Antioxidants have harmful effects that masks its useful antioxidant action-use of a better antioxidantCertain antioxidants are not effective in well nourished people-use of a proper antioxidantThe target is not well selected-to select the target (vectors in gene therapy, nano-carriers)
![Page 15: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/15.jpg)
Antioxidant drugs approved for clinical use in various diseases
Edaravone Ischemic stroke
Idebenone Alzheimer disease
N-Acetylcystine Mucolytic
α-Lipoic acid Diabetic neuropathy
Daflon 500 Persistent ulcers
![Page 16: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/16.jpg)
WHAT ARE THE REAL FUTURE PROSPECTS OF ANTIOXIDANTS IN CLINICAL PRACTICE1. Gene therapy2. Nano technology3. Genetically engineered plant products4. Synthetic antioxidant enzymes5. Functional food
![Page 17: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/17.jpg)
Gene therapyi. Transductionii. Vectorsiii. Common antioxidant genes that are
transduced TransductionDNA is transferred from one cell to another cell with the help of a virusiv. Generalisedv. Specialised
![Page 18: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/18.jpg)
![Page 19: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/19.jpg)
Vectors used for gene transferVector Advantages Disadvantages
Naked plasmid DNA Easy to produce Very low transduction efficacy
Adenovirus High transduction efficacy Inflammation with high dose
Adeno-associated virus Long term gene expression, moderate immune response, transduces quicent cells,
Limited trans gene capacity
Lentivirus Long term gene expression, transduces quicent cells, relatively high trans gene capacity
No specific integration
Retrovirus Long term gene expression Non specific integration, limited tropism
HSV-1 High transduction efficacy, high trans gene capacity
Transduces only dividing cells, cytotoxic
![Page 20: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/20.jpg)
Common antioxidant genes that are transducedi. Heme oxygenase-1ii. Superoxide dismutase'siii. Catalaseiv. Glutathione peroxidasev. Repair genes-a. Lipoprotein-Associated Phospholipase A2b. Guanosine 5-Triphospate Cyclohydrolase I
![Page 21: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/21.jpg)
Limitations in antioxidant gene therapy1. Limited duration of Transgene expression2. Limited Transduction of cells3. Immune Responses4. Role of ROS in cell signalingLimited duration of Transgene expressioni. Time course of the disease progressionii. Selection of the individuals without any signs of the
disease-benefit from gene therapyiii. Gene therapy-long term expression of desired targetsiv. Current diagnostic tests and gene therapy vectorsv. I/R injury or thrombosis-so suddenvi. High risk patients-refinement of current diagnostic tests
![Page 22: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/22.jpg)
Limited transduction of cells1. Limited efficacy of current vectors in
transduction of cells2. Wide spread delivery of trans genes is neededImmune ResponsesGene therapy vectors and transgenesIndividual variability in immune responseRole of ROS in Cell signalingROS-pathological events, normal cell signaling
![Page 23: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/23.jpg)
Future directions of gene therapy1. Ex vivo gene transfer of stem and progenitor cells-unwanted transduction of cells & tissues2. Identification of patients with genetic weakness in antioxidant defense system3.Vector modifications-alternate serotypes and capsid4. Transient immune suppression
![Page 24: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/24.jpg)
…..continue5. Use of transcription factors to elicit pleiotropic effects6. Development of regulatable vector systems-on and off as needed-a. promotors-orally administered drugsb. promotors-physiological stimuli (hypoxia)7. Development of novel gene delivery methods-biodegradable gels, gene-eluting stents8. Clinical potential of antioxidant gene therapy-EC-SOD-outside transduced cells-HO-1
![Page 25: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/25.jpg)
Nano technologyNanocarrier Antioxidants-low bioavailability, low biocompatibilityNanoparticles + antioxidants 1. Nanoantioxidants prepared by encapsulation2. Nanoantioxidants prepared by surface-functionalization methodNanoantioxidants prepared by encapsulationa. Chemical methods-polymerizationb. Physical methods-spray & freeze dryingc. Physicochemical-liposomeTwo methods1. Top-down methods2. Bottom-up methodsMaterials used for the preparation of nano-encapsulesi. Synthetic polymersii. Natural polymers
![Page 26: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/26.jpg)
Nano-antioxidants
![Page 27: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/27.jpg)
Chemical synthetic polymers used for antioxidants encapsulation
Nanoparticles Antioxidants Superiority Experimental mode
Eduragi E & polyvinyl alcohol
Quercetin ↑ Antioxidant activity In vitro
Poly & polyethylene glycol-5000
Curcumin ↑ cellular uptake, bioactivity & bioavailability
Rat, cell lines
Poly-b-poly Resveratrol ↑ solubility, stability Cell cultures
Gum Arabic-maltodextrin
Epigallocatechin gallate
Integrity & biological activity maintained
Cell lines, in vitro
Stearyl ferulate Β-carotene, α-tocopherol
↑ Stability In vitro
Poly acid Vitamin E, C ↑ Antioxidant activ In vitro
Polysulfide SOD ↑ Antioxidant activ, stability
In vitro
![Page 28: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/28.jpg)
![Page 29: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/29.jpg)
Significance of Nanoantioxidants encapsulation1. Permeability2. Aqueous solubility 3. Stability4. More surface5. Improvement of control release6. Target specificity7. Enhances therapeutic antioxidant efficacy
![Page 30: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/30.jpg)
Liposomes used in antioxidant encapsulation
![Page 31: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/31.jpg)
Significance of using liposomesi. Synthesized from natural productsii. Non-toxiciii. Biodegradableiv. No-immune response v. Target specific
![Page 32: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/32.jpg)
Nanoantioxidants prepared by surface-functionalization method1. Covalently linked to the surface of nanoparticle2. Enhances radical scavenging activity3. Kinetic enhancement effect of antioxidant activity
![Page 33: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/33.jpg)
Future directions of Nano-antioxidants 1. Having a targeting group that can reach the diseased organ or tissue specifically2. Avoiding release of the antioxidant monomers located inside nanocarriers during long-term circulation before they reach the target point3. Having high antioxidative activity4. No in vitro and in vivo cytotoxicity5. Having an appropriate administration route6. Easily be excreted from the body7. The rational design of nanotechnology materials and tools based around a detailed and thorough understanding of biological processes.
![Page 34: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/34.jpg)
Genetically engineered plant products1. Vegetables with high antioxidant compoundsEg; tomatoes-with up to 3 times lycopene concentration, longer shelf life2. Orange cauliflower-rich in carotene3. The Vegetable and Fruit Improvement Center at Texas-Super vegetables-purple carrot breed-40% more β-carotene4. Anti-carcinogenic properties of Citrus fruits5. Increasing the carotenoid content of watermelons6. Onions-↑ quercetin, anthocyanin7. Pepper-↑ quercetin8. Stone fruits-↑ anthocyanin
![Page 35: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/35.jpg)
![Page 36: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/36.jpg)
Functional foodsThey provide additional physiological benefits apart from the simple nutrition1. Whole foods- supplements or processed foods2. Indian foods constitute spices and medicinal plants-vitamins, nutrients and antioxidants3. Memory decline-low levels of dietary antioxidants4. Intake of fruits and vegetables with Oxygen Radical Absorbance Capacity (ORAC) 3000-5000/ day-significant impact
![Page 37: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/37.jpg)
![Page 38: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/38.jpg)
4.Bakery products-white breads with vitamins, fibers, microelements
5. Functional drinks-a. non alcoholic beverages fortified with-A,C, Eb. cholesterol lowering drinks with Omega-2 &
soyc. Eye health drinks-lutein6. Functional eggs-enriched with Antioxidants,
omega 3 FA
![Page 39: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/39.jpg)
Synthetic antioxidant enzymes1. They reduce tissue damage by reperfusion2. Lower molecular weight3. More stable4. No immune response5. Tempol-SOD mimetic drugi. Used in acute and chronic painii. Enhances the antitumour effects of –
interleukinsiii. Efficient radioprotector
![Page 40: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/40.jpg)
Summary1. Free radicals are having positive effects also2. Antioxidants are having negative effects also3. Appropriate use of antioxidants is required4. Gene therapy, nano technology, genetically
engineered plant products, synthetic enzymes, functional foods
![Page 41: Future scope of antioxidants in clinical medicine](https://reader030.vdocuments.us/reader030/viewer/2022020301/58a86f7d1a28ab90568b5259/html5/thumbnails/41.jpg)
Thank you